Nat Clin Pract Endocrinol Metab. 2006;2(4):180-181. The fact that PTC is associated with mutually exclusive alterations to MAPK pathway effectors offers intriguing therapeutic opportunities. Ras ...

Biomarker-informed therapeutic decision-making is the standard of care for malignancies with targetable genetic alterations, including BRAF mutations. It is crucial to ensure clear and consistent ...

Explore the challenges and advancements in anti-EGFR antibody treatment for metastatic colorectal cancer. Discover how ...

About 40% of ATC tumors have mutations in the BRAF gene that help drive the cancers' behavior and prognosis. The new trial focused on 42 patients battling a BRAF-mutated ATC. The median overall ...

Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in the body.

The data suggest that the three-drug combination should replace chemotherapy for one in seven patients with metastatic colorectal cancer who have a BRAF mutation, according to lead investigator ...

Genomic assessment by whole-exome sequencing in 28 evaluable patients revealed expected alterations: BRAF V600E mutations in six patients with DTC subtype and three with ATC. NRAS variant was ...

In combination with dabrafenib for the treatment of pediatric patients with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. <1yr or <8kg: not established.

A new clinical trial highlights that spotting a genetic subtype of these ATC tumors can be key to designing treatment that greatly extends survival ATC patients with BRAF gene mutations lived a ...